In the current literature, infection with the hepatitis B virus (HBV) is described as one of the main risk factors for the development of hepatocellular carcinoma (HCC).
According to the current study situation, the Hepatitis B surface antigen (HBsAg) is considered as an important marker, since low levels and sero-clearance of HBsAg are both correlated with a lower risk of HCC development / recurrence.Currently there is no treatment option available that efficiently targets HBsAg. Besides neutralizing infectious HBV virions, Hepatitis B immunoglobulins (HBIG) can directly bind and neutralize extracellular HBsAg/SVPs, and even intracellular HBsAg targeting is reported. In addition, HBIGs can initiate effector-cell attack (via antibody-dependent cellular cytotoxicity, ADCC) towards infected hepatocytes.
The potential benefit of HBIGs in the HCC context is further underlined by recent evidence for the ability of HBIGs to reduce the viability, proliferation, and self-renewal of tumor-initiating cells (TICs) - isolated from HBV-HCC patients - accompanied by downregulation of stemness markers, e.g., OCT-4.According to the current study situation, the use of HBIGs significantly reduces the risk of HBV reinfection after transplantation and improves the results of liver transplantation in patients with chronic HBV infection. The potential benefit of treating HBV-HCC patients on the LTx (liver transplantation) waiting list with hepatitis B immunoglobulin is the possible stop or inhibition of tumor progression while waiting for an LTx. So far there is no clinical evidence of this.
Mechanistically, hepatitis B immunoglobulin could occur through neutralization of circulating HBsAg, which is an important driver of an immunosuppressive environment in HBV patients, and possibly through direct effects against HBV HCC tumor cells (through antibody-dependent cellular cytotoxicity, ADCC). Therefore, the idea behind preoperative HBIG administration before liver transplantation is to reduce the rate of patients in whom a transplantation would no longer have been possible due to tumor progression. Thus, due to tumor progression in HBV-positive HCC-patients there is a monthly drop-out from the waiting list of about 4%.
The basic idea behind the treatment of HBV-HCC patients before tumor resection with hepatitis B immunoglobulin is to potentially stop or positively influence tumor progression through the effects mentioned above, in the time between diagnosis and resection.
Zhou et al. (2015) have shown a connection between HBsAg levels and HCC relapses after resection, although the exact role of HBsAg is still unclear. In no case will the treatment postpone the time of tumor resection, as only patients are considered who, for clinical reasons, can expect a certain time until resection. The present proof of concept study aims to quantify HBsAg reduction due to preoperative administration of HBIGs in HBV-positive HCC-patients and serve as a template for future multicentre clinical trials.

Start Date01 Nov 2024

Sponsor / Collaborator

Medizinische Universität Graz

NCT04629651 / WithdrawnPhase 1/2IIT

Phase I/II Prospective Trial Investigating the Safety and Efficacy of Captopril Use on the Degree of Marrow Fibrosis in Patients With Primary or Secondary Bone Marrow Fibrosis/Myeloproliferative Neoplasms

The purpose of this study is to evaluate the safety and tolerability of captopril and evaluate the effectiveness captopril as measured by changes in the grade of bone marrow scar tissue. The change in spleen size by ultrasound will also be measured.

Start Date01 Apr 2024

Sponsor / Collaborator

The Case Comprehensive Cancer Center

NCT06292091 / CompletedPhase 1IIT

An Open-label, Fixed-sequence, 3-period Crossover Exploratory Study to Investigate the Effect of Urine Acid-base Disequilibrium on the Pharmacokinetics of Captopril in Healthy Male Volunteers

The aim of this study is to evaluate the effect of urine acid-base disequilibrium on the pharmacokinetics of captopril in healthy male volunteers.

Start Date28 Feb 2024

Sponsor / Collaborator

Seoul National University Hospital

100 Clinical Results associated with Captopril

100 Translational Medicine associated with Captopril

100 Patents (Medical) associated with Captopril

18,772

Literatures (Medical) associated with Captopril

31 Dec 2024·Gut Microbes

Prescription opioids induced microbial dysbiosis worsens severity of chronic pancreatitis and drives pain hypersensitivity

Article

Author: Tao, Junyi ; Jalodia, Richa ; Ghosh, Nillu ; Dawra, Rajinder ; Kesh, Kousik ; Singh, Salma ; Roy, Sabita

Opioids, such as morphine and oxycodone, are widely used for pain management associated with chronic pancreatitis (CP); however, their impact on the progression and pain sensitivity of CP has never been evaluated. This report investigates the impact of opioid use on the severity of CP, pain sensitivity, and the gut microbiome. C57BL/6 mice were divided into control, CP, CP with morphine/oxycodone, and either morphine or oxycodone alone groups. CP was induced by administration of caerulein (50ug/kg/h, i.p. hourly x7, twice a week for 10 weeks). The mouse-to-pancreas weight ratio, histology, and Sirius red staining were performed to measure CP severity. Tail flick and paw pressure assays were used to measure thermal and mechanical pain. DNA was extracted from the fecal samples and subjected to whole-genome shotgun sequencing. Germ-free mice were used to validate the role of gut microbiome in sensitizing acute pancreatic inflammation. Opioid treatment exacerbates CP by increasing pancreatic necrosis, fibrosis, and immune-cell infiltration. Opioid-treated CP mice exhibited enhanced pain hypersensitivity and showed distinct clustering of the gut microbiome compared to untreated CP mice, with severely compromised gut barrier integrity. Fecal microbiota transplantation (FMT) from opioid-treated CP mice into germ-free mice resulted in pancreatic inflammation in response to a suboptimal caerulein dose. Together, these analyses revealed that opioids worsen the severity of CP and induce significant alterations in pain sensitivity and the gut microbiome in a caerulein CP mouse model. Microbial dysbiosis plays an important role in sensitizing the host to pancreatic inflammation.

01 Dec 2024·European Journal of Pharmacology

Captopril inhibits the overproduction of proopiomelanocortin and adrenocorticotropic hormone in the pituitary gland of male diabetic mice in close relationship with an increase in glucocorticoid receptor expression

Article

Author: Chaves, Amanda da Silva ; Magalhães, Nathalia Santos ; Rodrigues e Silva, Patrícia Martins ; da Silva Chaves, Amanda ; Reis Insuela, Daniella Bianchi ; Carvalho, Vinicius Frias ; Silva, Patrícia Machado Rodrigues E ; Insuela, Daniella Bianchi Reis ; Martins, Marco Aurélio

Prior investigation shows that diabetic patients present hypothalamus-pituitary-adrenal (HPA) axis hyperactivity related to impaired negative feedback. This study investigates the effect of Captopril on the overproduction of adrenocorticotropic hormone (ACTH) and its precursor proopiomelanocortin (POMC) in the pituitary gland of male diabetic mice. Diabetes was induced by intravenous injection of alloxan into fasted Swiss-webster mice, and the animals were treated with Captopril for 14 consecutive days, starting 7 days post-diabetes induction. Plasma corticosterone levels were evaluated by ELISA, while pituitary gland expressions of angiotensin-II type 1 receptor (AT₁), angiotensin-II type 2 receptor (AT₂), ACTH, Bax, Bcl-2, KI-67, POMC, and glucocorticoid receptor (GR) were evaluated using immunohistochemistry or Western blot. Diabetic mice showed pituitary gland overexpression of AT₁, without altering AT₂ levels, which were sensitive to Captopril treatment. Furthermore, diabetic mice presented hypercortisolism, along with an increase in the number of corticotroph cells, POMC and ACTH expression, and number of proliferative cells, and a decrease of GR expression in the pituitary gland. In addition, treatment with Captopril reduced systemic corticosterone levels, corticotroph and proliferative cell numbers, and Bcl-2, POMC, and ACTH expression in the pituitary gland of diabetic mice, besides increasing the expression of Bax and GR. In conclusion, these findings show that Captopril is a promising therapy for treating complications associated with HPA axis hyperactivity in diabetic patients, in a mechanism probably related to the downregulation of POMC production in the pituitary gland and subsequent reduction of systemic corticosterone levels.

01 Nov 2024·European Journal of Pharmaceutics and Biopharmaceutics

Pediatric oral extemporaneous preparations and practices: International Pharmaceutical Federation (FIP) global study

Article

Author: Şeremet, Gökhan ; Li, Zhiping ; Iurian, Sonia ; Carvalho, Maria ; Dassouki, Hadi ; Hamid, Aasma ; Fadda, Hala M ; Pauletti, Giovanni M ; Pauletti, Giovanni M. ; Minghetti, Paola ; Lee, You Zhuan ; Tuleu, Catherine ; AbuBlan, Rasha ; Fadda, Hala M. ; Weiler, Hannah

This publication is the first to report current, global, pediatric oral extemporaneous compounding practices. Complete survey responses were received from 479 participants actively involved in compounding across all the World Health Organization (WHO) regions. The survey addressed oral formulation of extemporaneous liquids, including the use of commercial or in-house vehicles, flavoring excipients, source of formulation recipes, and beyond use dates (BUDs). Over 90% of the survey participants prepared oral liquids. Solid dosage forms, comprising capsules and powder papers (sachets), were also frequently prepared for children, albeit to a lesser extent. The top 20 active pharmaceutical ingredients compounded for children, globally, were: omeprazole, captopril, spironolactone, propranolol, furosemide, phenobarbital, hydrochlorothiazide, ursodeoxycholic acid, sildenafil, melatonin, clonidine, enalapril, dexamethasone, baclofen, caffeine, chloral hydrate, trimethoprim, atenolol, hydrocortisone, carvedilol and prednisolone. Diuretics, drugs for acid-related disorders, and beta-blockers were the top three most frequently compounded classes per the WHO Anatomical Therapeutic Chemical (ATC) classification system. The principal need identified for the practice of extemporaneous compounding for children was the development of an international, open-access formulary that includes validated formulations, as well as updated compounding literature and guidelines. Furthermore, improved access to data from stability studies to allow compounding of formulations with extended BUDs.

News (Medical) associated with Captopril

21 Jun 2024

·www.drugs.com

Angiotensin Receptor Blocker Use Linked to Lower Incidence of Epilepsy

FRIDAY, June 21, 2024 -- For patients with hypertension, angiotensin receptor blockers (ARBs) are associated with a reduced incidence of epilepsy compared with other antihypertensive medications, according to a study published online June 17 in JAMA Neurology . Xuerong Wen, Ph.D., from the University of Rhode Island in Kingston, and colleagues conducted a retrospective cohort study to examine the association between ARB use and epilepsy incidence in subgroups of U.S. patients with hypertension. Patients who received ARBs were propensity score (PS)-matched to those who received angiotensin-converting enzyme inhibitors (ACEIs), β-blockers, calcium channel blockers (CCBs), or a combination of these medications. Of the participants, 309,978 received ARBs, 807,510 received ACEIs, 695,887 received β-blockers, and 448,589 received CCBs; the 1:1 PS-matched subgroups included 619,858 patients for ARB versus ACEI, 619,828 patients for ARB versus β-blocker, and 601,002 patients for ARB versus CCB. The researchers found that the incidence of epilepsy was reduced with use of ARBs versus ACEs, β-blockers, and a combination of other antihypertensive classes (adjusted hazard ratios, 0.75, 0.70, and 0.72, respectively). In subgroup analyses, the investigators observed a significant association between ARB use (mainly losartan) and epilepsy incidence in patients with no preexisting history of stroke or cardiovascular disease. "Further pharmacological studies, including randomized clinical trials, are needed to establish antiepileptogenic properties of antihypertensive medications," the authors write. Two authors disclosed ties to the pharmaceutical and medical device industries.

Clinical Result

14 May 2024

·www.prnewswire.com

CardioPharma Announces Issuance of Global Patent to Mitigate the World's Top Killer

WILMINGTON, N.C., May 14, 2024 /PRNewswire/ -- CardioPharma Inc. (the "Company"), a specialty pharmaceutical company focused on drug development for cardiovascular diseases, announced that on August 29, 2023, the United States Patent and Trademark Office ("USPTO") issued US Patent 11,737,988 B2 entitled "Anti-Hypertensive and Cholesterol-Lowering Fixed-Dose Combination and Method of Manufacture." Additional patents covering the subject matter of the '988 Patent have been granted in South Africa in 2022 and Australia, Armenia, Belarus, and the Russian Federation in 2024. Three further patents have been accepted in Canada, New Zealand, and Israel and will issue in the near future. In addition to the foregoing, CardioPharma is pursuing additional patents in major markets throughout the world, all of which together will bolster CardioPharma's global presence for the products covered by the patent grants. The 20-year term for all of the patents runs through April 17, 2039. CardioPharma Pipeline CardioPharma's pipeline products contain some of the world's most consumed, individually dispensed medications for the prevention and treatment of cardiovascular disease. The lead product, CardiaPill® is a unique formulation combining a cholesterol modifying agent ("statin"), an Angiotensin-converting-enzyme inhibitor (ACE Inhibitor) and anti-platelet agent. Statins moderate cholesterol levels and include products such as Lipitor®, Zocor®, Pravachol®; and Crestor®. ACE inhibitors reduce blood pressure and include products such as Altace®, Lotensin®, Capoten® and Accupril®. Pipeline products also include combinations using Angiotensin II Receptor Blockers (ARBs) as well as different statins and other anti-platelet agents. Simplicity of dosing, improved adherence and significant cost benefits for patients, providers and payors around the world are among the many compelling and well-documented benefits that make these inexpensive products so anticipated. About CardioPharma CardioPharma (), Inc. is a specialty pharmaceutical company focused on patent-protected combinatorial cardiovascular medications. CardioPharma's goal is to create drugs that make it easier and more cost-effective for doctors and their patients to reduce the morbidity and mortality of the world's number one killer – cardiovascular disease. The products are unique to the global pharmaceutical industry – highly cost-effective with proven efficacy; providing both patient and provider convenience; promoting adherence, while delivering superior clinical outcomes and economic benefits to all stakeholders. For more information, visit . Forward looking statements The information in this press release contains forward-looking statements including the prospective development, commercialization and regulatory approval in the U.S. and international markets. Words such as "expects," "plans," "believe," "may," "will," "anticipated," "intended" and variations of these words or similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors including the Company's ability to raise sufficient funds to bring new products to the global market. Contact: [email protected] SOURCE CardioPharma, Inc.

Patent Expiration

28 Sep 2022

·www.biospace.com

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data for Baxdrostat in Treatment-Resistant Hypertension at the Upcoming 2022 American Heart Association Scientific Sessions

WALTHAM, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 2 data from its BrigHtn trial evaluating baxdrostat in patients with treatment-resistant hypertension as part of the late-breaking science session at the upcoming 2022 American Heart Association (AHA) Scientific Sessions taking place November 5-7, 2022, virtually and in Chicago, Illinois. Baxdrostat is a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase. The presentation will include clinical data from CinCor’s BrigHtn trial, a Phase 2 randomized, double-blind, multicenter, placebo-controlled dose-ranging study designed to assess the safety and efficacy of baxdrostat in subjects who have not achieved their target blood pressure despite receiving three or more antihypertensive agents at their maximally tolerated doses, one of which must be a diuretic. “We believe baxdrostat provides the first new mechanism to lower aldosterone levels for the treatment of hypertension since the development of ACEIs and ARBs over 30 years ago,” said Mason Freeman, M.D., Chief Medical Officer at CinCor. “We are pleased to present data from our BrigHtn trial demonstrating baxdrostat can potentially be used in combination with those older agents to provide greater blood pressure lowering in patients whose hypertension is refractory to treatment.” Results From a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Baxdrostat in Patients with Treatment-Resistant Hypertension Date/Time: November 7, 2022 Presenter: Mason Freeman M.D, Chief Medical Officer at CinCor Session Title: LBS.09 - Late-Breaking Science: Resistant Hypertension: A Pressure Cooker Please visit the AHA Scientific Sessions Late-Breaking Science for the most current programming. About CinCor CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, baxdrostat, a highly selective, oral small molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism. About Baxdrostat Baxdrostat (CIN-107) is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for patient populations with significant unmet medical needs, including treatment-resistant hypertension and primary aldosteronism. Hypertension, which is defined by the American College of Cardiology and the American Heart Association as resting blood pressure above 130/80 mm Hg, is generally acknowledged to be one of the most common preventable risk factors for premature death worldwide. Though often asymptomatic, hypertension significantly increases the risk of heart disease, stroke and kidney disease, amongst other diseases. It is estimated that as much as 20% of the global population suffers from hypertension, including nearly one-half of the adult population in the U.S., or 116 million hypertensive patients. Forward-Looking Statements This press release contains certain forward-looking statements, including, but not limited to, the therapeutic potential of baxdrostat (CIN-107), including expectations with respect to baxdrostat providing the first new mechanism to lower aldosterone levels for the treatment of hypertension since the development of ACEis and ARBs over 30 years ago, baxdrostat’s potential to be used in combination with those older agents to provide greater blood pressure lowering for those whose hypertension is refractory to treatment and the ability of baxdrostat to address multiple unmet needs in patients; expectations with respect to regulatory matters; and other statements that are not historical facts. Because such statements are subject to risks and uncertainties, actual results may differ from those expressed or implied by such forward-looking statements. Words such as “anticipates,” “believes,” “expected,” “intends,” “plan,” “may”, “will,” “project”, “estimate”, “continue,” “advance” and “future” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on CinCor’s current plans, objectives, estimates, expectations and intentions, involve assumptions that may never materialize or may prove to be incorrect and inherently involve significant risks and uncertainties, including factors beyond CinCor’s control, that could cause actual results, performance, or achievement to differ materially and adversely from those anticipated or implied in the statements, including, without limitation, CinCor has incurred significant operating losses since its inception; CinCor has a limited operating history and no history of commercializing products; CinCor will require substantial additional funding to finance its operations; CinCor’s business is entirely dependent at this time on the success of one drug, baxdrostat; initial, interim, “top-line” and preliminary data from clinical trials announced or published from time to time may change; CinCor may not be successful in its efforts to expand its pipeline beyond baxdrostat; success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials; enrollment and retention of patients in clinical trials could be delayed; CinCor relies and will rely on third parties to conduct, supervise and monitor existing clinical trials and potential future clinical trials; developments from the company’s competitors and the marketplace for the company’s products; and CinCor’s business, operations and clinical development timelines and plans may be adversely affected by the evolving and ongoing COVID-19 pandemic, geopolitical events, including the ongoing military conflict between Russia and Ukraine and related sanctions against Russia, and macroeconomic conditions, including rising inflation and uncertain credit and financial markets, and matters related thereto; and other risks and uncertainties affecting the company, including those described under the caption “Risk Factors” and elsewhere in CinCor’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC) on March 22, 2022, quarterly report on Form 10-Q for the three months ended June 30, 2022 filed with the SEC on August 8, 2022, and other filings and reports that CinCor may time to time with the SEC. Other risks and uncertainties of which CinCor is not currently aware may also affect the company’s forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. CinCor undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Contacts: Investors: Terry Coelho Bob Yedid CinCor Pharma, Inc. LifeSci Advisors EVP, CFO and CBDO ir@CinCor.com

Small molecular drugAHA

100 Deals associated with Captopril

External Link

KEGG	Wiki	ATC	Drug Bank
D00251	Captopril	C09AA01	DB01197

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Essential Hypertension	JP	Alfresa Pharma Corp.	07 Oct 1982
Hypertension, Malignant	JP	Alfresa Pharma Corp.	07 Oct 1982
Hypertension, Renovascular	JP	Alfresa Pharma Corp.	07 Oct 1982
Hypertensive Nephropathy	JP	Alfresa Pharma Corp.	07 Oct 1982
Diabetic Nephropathies	JP	Daiichi Sankyo Co., Ltd.	01 Jan 1980
Heart Failure	JP	Daiichi Sankyo Co., Ltd.	01 Jan 1980
Hypertension	JP	Daiichi Sankyo Co., Ltd.	01 Jan 1980
Myocardial Infarction	JP	Daiichi Sankyo Co., Ltd.	01 Jan 1980

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03179163 (H2SPharm, CTgov)	Phase 1/2	Essential Hypertension	10	Captopril	drukjqbona(lyljjepebc) = yczqfhgjyq olgmldrogj (uvucxdaicx, dcfzovxdhf - gpiwnuxeaa) View more	-	28 Feb 2024
AtTEnd (ESMO2023)	Phase 3	Recurrent Endometrial Cancer	-	CP chemotherapy and atezolizumab	(mzpydczusm) = owuzdskphm liqwmrzzvt (wukuougylu ) View more	Positive	21 Oct 2023
				Placebo	(mzpydczusm) = hfhblvacsm liqwmrzzvt (wukuougylu ) View more
ISN WCN2022	Not Applicable	Acute Tubulointerstitial Nephritis	1	Captopril	roynzhubjz(wlvepdgbqw) = evllqmbjzw auciynzunj (rnjalzyxmo ) View more	Positive	01 Feb 2022
NCT01669434 (CTgov)	Phase 4	Hypotension	291	LISINOPRIL+Captopril+ENALAPRILAT+BENAZEPRIL HYDROCHLORIDE+PERINDOPRIL ERBUMINE+RAMIPRIL+QUINAPRIL HYDROCHLORIDE+Enalapril Maleate+Perindopril Arginine+FOSINOPRIL SODIUM+TRANDOLAPRIL+MOEXIPRIL HYDROCHLORIDE (ACEI Omission)	pqgvdxvrax(nyqljnlpsg) = bmgwskrsin gxtnpgzlyi (voxzuavbfk, trncelqgam - ckhuyjoxym) View more	-	11 Dec 2017
				ACEI continuation (ACEI Continuation)	pqgvdxvrax(nyqljnlpsg) = smxiicjmwa gxtnpgzlyi (voxzuavbfk, phyvadhvsv - lhoinfhlfu) View more
ASN2014	Not Applicable	Hypertension	-	Captopril	jfgfqbcotb(ifjfqlxnpp) = eonzuwwjxn qdvimfyvrj (nmixfofkyv ) View more	-	11 Nov 2014
				Vehicle	jfgfqbcotb(ifjfqlxnpp) = gaauhlkiel qdvimfyvrj (nmixfofkyv ) View more
NCT00660309 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	45	Captopril+Aliskiren (Aliskiren)	mrzfpgijhz(djkkxldyta) = nvkezoxign tcrqiwhsyd (beqixjgqmw, wcaubmlgbn - xgjwszxkha) View more	-	29 Aug 2012
				Captopril+Irbesartan (Irbesartan)	mrzfpgijhz(djkkxldyta) = junpcqfkyb tcrqiwhsyd (beqixjgqmw, dvqrrxikte - qdhwdvhfky) View more
ARVO2012	Not Applicable	Diabetic Retinopathy	317	Captopril	xjivkhjysi(pxjqclmmck) = hrrvaispjr hpymwnxpic (udswwrkdku ) View more	-	01 Mar 2012
				Vitamin C	xjivkhjysi(pxjqclmmck) = qigaflstek hpymwnxpic (udswwrkdku ) View more
ORAL SOLO (A3921045) (EULAR2011)	Phase 3	Rheumatoid Arthritis	610	CP 5 mg BID	(qgwcjjftey) = gxoxdmoahj lkbsmupmao (dblnzgdeku )	Positive	25 May 2011
				CP 10 mg BID	(qgwcjjftey) = wtzupljvwr lkbsmupmao (dblnzgdeku )
ASN2010	Not Applicable	-	-	ACEIs	trlbvgtjmf(dqxxikyrch) = lcvvcyhrqf yxvypsdmaz (zdisknalai )	-	16 Nov 2010
				ARBs	usmcswlrlv(ezdwwqplek) = moxxvewqmp zefkynomtr (lydyhybkti ) View more
ASN2010	Not Applicable	Bone marrow transplant rejection	-	Captopril	(asehlktmic) = jxbqmrnmxj fephjwfqbf (hlipyskpfs )	Positive	16 Nov 2010
				Captopril	(asehlktmic) = fetdanmqjm fephjwfqbf (hlipyskpfs )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis